Company Performance Metrics
- Chiara Heide: Founder & CEO
- Simon May: Co-Founder and CBO
Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant
infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract.
BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.
